BlackRock Inc. Takes Position in Yarrow Bioscience $YARW

Key Points

• BlackRock acquired 44,405 shares of Yarrow Bioscience, worth approximately $29,000, giving it a 6.63% stake. Institutional investors collectively own 83.78% of the company.
• Yarrow Bioscience reported a quarterly loss of $3.51 per share, missing the $0.18 consensus estimate, while revenue of $0.10 million was below the $0.20 million forecast. The stock opened at $29.11, within its 12-month range of $14.17 to $46.95.
• The company paid a $19 special dividend; analysts have a consensus “Hold” rating and an average price target of $58, with two Buy ratings and one Sell rating.

BlackRock Inc. bought a new stake in shares of Yarrow Bioscience (NASDAQ:YARW - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 44,405 shares of the company's stock, valued at approximately $29,000. BlackRock Inc. owned about 6.63% of Yarrow Bioscience as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Anson Funds Management LP acquired a new stake in shares of Yarrow Bioscience during the fourth quarter valued at $739,000. Nantahala Capital Management LLC acquired a new stake in shares of Yarrow Bioscience during the 4th quarter worth about $580,000. T3 Companies LLC acquired a new stake in shares of Yarrow Bioscience during the 4th quarter worth about $548,000. ADAR1 Capital Management LLC grew its holdings in shares of Yarrow Bioscience by 319.2% during the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company's stock worth $636,000 after buying an additional 810,108 shares in the last quarter. Finally, KVP Capital Advisors LP purchased a new stake in shares of Yarrow Bioscience during the fourth quarter worth about $290,000. Hedge funds and other institutional investors own 83.78% of the company's stock.

Yarrow Bioscience Stock Performance

Shares of Yarrow Bioscience stock opened at $29.11 on Thursday. Yarrow Bioscience has a twelve month low of $14.17 and a twelve month high of $46.95. The firm has a market capitalization of $77.72 million, a P/E ratio of -1.99 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) EPS for the quarter, missing the consensus estimate of ($0.18) by ($3.33). Yarrow Bioscience had a negative return on equity of 84.40% and a negative net margin of 4,726.21%.The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million.

Yarrow Bioscience Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were given a $19.00 dividend.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Yarrow Bioscience to a "hold" rating in a research report on Saturday, August 22nd. BTIG Research initiated coverage on Yarrow Bioscience in a report on Monday, August 3rd. They issued a "buy" rating and a $58.00 price target for the company. Finally, TD Cowen began coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They set a "buy" rating on the stock. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Yarrow Bioscience has a consensus rating of "Hold" and a consensus target price of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

Want to see what other hedge funds are holding YARW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Yarrow Bioscience (NASDAQ:YARW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.